Novo Nordisk looks to get into the factor 8 market
Neose Technologies, Inc. announced that it received a milestone payment from Novo Nordisk under a license agreement for the use of Neose's GlycoPEGylation technology to develop a next-generation version of recombinant Factor VIII.
Neose is also working on development of longer-lasting r-FVIIa and r-FIX.
Showing posts with label Neose Technologies. Show all posts
Showing posts with label Neose Technologies. Show all posts
Friday, February 8, 2008
Subscribe to:
Posts (Atom)
